Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E Cetuximab rectum cancer resistant detail...
BRAF V600E Panitumumab rectum cancer resistant detail...
NRAS exon2 Cetuximab rectum cancer resistant detail...
NRAS exon2 Panitumumab rectum cancer resistant detail...
NRAS exon4 Cetuximab rectum cancer resistant detail...
NRAS exon4 Panitumumab rectum cancer resistant detail...
NRAS exon3 Cetuximab rectum cancer resistant detail...
NRAS exon3 Panitumumab rectum cancer resistant detail...
NTRK1 fusion Larotrectinib rectum cancer sensitive detail...
MLH1 mutant N/A rectum cancer not applicable detail...
MSH6 mutant N/A rectum cancer not applicable detail...
BRAF V600E Encorafenib + Panitumumab rectum cancer sensitive detail...
BRAF V600E Cetuximab + Encorafenib rectum cancer sensitive detail...
BRAF wild-type Cetuximab rectum cancer predicted - sensitive detail...
NRAS wild-type Cetuximab rectum cancer predicted - sensitive detail...
NRAS wild-type Panitumumab rectum cancer predicted - sensitive detail...
BRAF wild-type Panitumumab rectum cancer predicted - sensitive detail...
MLH1 negative Dostarlimab-gxly rectum cancer sensitive detail...
MSH6 negative Dostarlimab-gxly rectum cancer sensitive detail...
NTRK2 fusion Entrectinib rectum cancer sensitive detail...
NTRK1 fusion Entrectinib rectum cancer sensitive detail...
NTRK2 fusion Larotrectinib rectum cancer sensitive detail...
MLH1 negative Pembrolizumab rectum cancer sensitive detail...
MSH6 negative Pembrolizumab rectum cancer sensitive detail...
MLH1 negative Nivolumab rectum cancer sensitive detail...
MSH6 negative Nivolumab rectum cancer sensitive detail...
MLH1 negative Ipilimumab + Nivolumab rectum cancer sensitive detail...
MSH6 negative Ipilimumab + Nivolumab rectum cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01274624 Phase I Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Pelareorep Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer Completed USA 0
NCT01309126 Phase III Cetuximab Cetuximab + PGG beta-glucan Study of Imprime PGG in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Terminated USA | FRA | DEU 1
NCT01740648 Phase I Fluorouracil + Trametinib Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer Active, not recruiting USA 0
NCT01966289 Phase I Cyclophosphamide Guadecitabine GVAX colorectal cancer vaccine SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) Completed USA 0
NCT01985763 Phase Ib/II Genistein Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Genistein in Treatment of Metastatic Colorectal Cancer Completed USA 0
NCT02041481 Phase I Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer Completed USA 0
NCT02199236 Phase I Capecitabine + Fluorouracil Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management Active, not recruiting USA 0
NCT02399813 Phase Ib/II ADXS11-001 Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum Completed USA 0
NCT02508077 Phase II Fluorouracil + Irinotecan + Leucovorin Panitumumab FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Terminated USA 0
NCT02890758 Phase I ALT-803 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Active, not recruiting USA 0
NCT03127098 Phase Ib/II ALT-803 + ETBX-011 QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer Completed USA 0
NCT03152370 Phase I E7046 + Fluorouracil + Leucovorin + Oxaliplatin Capecitabine + E7046 Preoperative Radiotherapy and E7046 in Rectum Cancer (PRAER 1) Completed USA 2
NCT03317119 Phase I Trametinib + Trifluridine-tipiracil hydrochloride Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT03516708 Phase Ib/II Pembrolizumab Epacadostat Capecitabine + Oxaliplatin Epacadostat (INCB024360) and Pembrolizumab Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer Recruiting USA 0
NCT03770689 Phase Ib/II Capecitabine Capecitabine + Peposertib Phase Ib/II Study of M3814 in Combination With Capecitabine and Radiotherapy in Rectal Cancer Completed USA | ESP 0
NCT03829410 Phase Ib/II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation Recruiting USA 0
NCT04124601 Phase II Capecitabine Capecitabine + Ipilimumab + Nivolumab Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer (CHINOREC) Recruiting AUT 0
NCT04293419 Phase II Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer (DUREC) Recruiting ESP 0
NCT04294160 Phase I Dabrafenib + LTT462 + Spartalizumab Dabrafenib + LTT462 + TNO155 Dabrafenib + TNO155 + Trametinib Dabrafenib + LTT462 Dabrafenib + LTT462 + LXH 254 Dabrafenib + LTT462 + Trametinib A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer Recruiting USA | ESP | DEU | CAN | BEL 5
NCT04486378 Phase II RO7198457 A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer Recruiting USA | ESP | DEU | BEL 0
NCT04926324 Phase Ib/II Dostarlimab-gxly + Niraparib A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers Recruiting USA 0
NCT05197322 Phase II Pembrolizumab NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer (NEOPRISM-CRC) Recruiting 1